WHO pandemic accord negotiations under time pressure
"Having a framework that brings nations together and plans for the next pandemic will save thousands if not millions of lives," insisted WHO emergencies director Michael Ryan.
But President Donald Trump's decision to withdraw the United States from the World Health Organization and his large-scale dismantling of US health institutes is a new threat to the global health risk surveillance system, experts warn.
"It's now or never," said Sueri Moon, co-director of the Global Health Centre at the Geneva Graduate Institute.
In December 2021, WHO member states resolved to seek a deal aimed at preventing and preparing for future pandemics, to avoid the mistakes made during Covid.
Major disputes have slowed negotiations, including on how to share data on dangerous pathogens, and whether the transfer of the technology and know-how to produce vaccines, tests and treatments should be mandatory or voluntary.
'
Unpredictable
'
After 13 rounds of discussions, countries have been meeting at the WHO headquarters in Geneva for final negotiations this week, with a Friday night deadline to iron out remaining problems.
The aim is to have a text ready for final approval during the WHO's annual assembly next month.
"The member states are working very hard," WHO chief Tedros Adhanom Ghebreyesus told reporters on Thursday, adding: "I hope they will reach a deal."
Ryan added that the negotiators were "making steady progress. But there are difficult issues on the table."
The number of disputed issues have steadily shrunk in recent months, with observers saying the main sticking point now is "political will".
The outcome is "unpredictable", a diplomatic source said.
"Substantial progress" has been made on the draft text, "but differences remain on some key articles", China's mission in Geneva told AFP, calling on all parties to "display mutual understanding" to secure an agreement that is "meaningful, equitable and actionable".
'Very important'
A new extension of the talks until May is possible, with NGOs and experts urging countries to compromise.
"It's very important to reach this agreement, even with a sub-optimal text," said Ellen 't Hoen, director of the Medicines Law and Policy NGO.
"That is much more preferable than having to negotiate such an agreement from scratch, because that will likely only happen after the next pandemic hits, and that would be an unacceptable situation."
Among the remaining sticking points are a so-called Pathogen Access and Benefit-Sharing System (PABS) proposed in the text.
The proposal calls for participating companies to provide the WHO with "rapid access" to 20 percent of their production of pandemic-related health products, including "at least 10 percent of their real time production" in the form of donations.
Some countries, especially producer states, have meanwhile balked at what they consider high thresholds.
While the talks could in theory continue even after next month's assembly, there is widespread concern that if the process drags on, the political will to conclude a deal would dissipate.
If that happens, "it will probably be too late", Moon said.
"The wind will go out of the sails."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Zawya
14 hours ago
- Zawya
World Health Organization (WHO) recommends injectable lenacapavir for Human Immunodeficiency Virus (HIV) prevention
The World Health Organization (WHO) released today new guidelines recommending the use of injectable lenacapavir (LEN) twice a year as an additional pre-exposure prophylaxis (PrEP) option for HIV prevention, in a landmark policy action that could help reshape the global HIV response. The guidelines are being issued at the 13th International AIDS Society Conference (IAS 2025) on HIV Science, in Kigali, Rwanda. LEN, the first twice-yearly injectable PrEP product, offers a highly effective, long-acting alternative to daily oral pills and other shorter-acting options. With just two doses per year, LEN is a transformative step forward in protecting people at risk of HIV – particularly those who face challenges with daily adherence, stigma, or access to health care. 'While an HIV vaccine remains elusive, lenacapavir is the next best thing: a long-acting antiretroviral shown in trials to prevent almost all HIV infections among those at risk," said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. 'The launch of WHO's new guidelines, alongside the FDA's recent approval, marks a critical step forward in expanding access to this powerful tool. WHO is committed to working with countries and partners to ensure this innovation reaches communities as quickly and safely as possible.' The new guidelines come at a critical moment as HIV prevention efforts stagnate with 1.3 million new HIV infections occurring in 2024 – with disproportionate impact among key and priority populations, including sex workers, men who have sex with men, transgender people, people who inject drugs, people in prisons, and children and adolescents. WHO's recommendation on LEN signals a decisive move to expand and diversify HIV prevention, giving people more options to take control over their health with choices that fit their lives. Simplified testing: a major barrier removed As part of these guidelines, WHO has recommended a public health approach to HIV testing using HIV rapid tests to support delivery of long-acting injectable PrEP, including LEN and cabotegravir (CAB-LA). The simplified testing recommendation removes a major access barrier by eliminating complex, costly procedures and enabling community-based delivery of long-acting PrEP through pharmacies, clinics, and tele-health. Next steps: call for implementation LEN joins other WHO-recommended PrEP options, including daily oral PrEP, injectable cabotegravir and the dapivirine vaginal ring, as part of a growing arsenal of tools to end the HIV epidemic. While access to LEN outside clinical trials remains limited at the moment, WHO urges governments, donors and global health partners to begin rolling out LEN immediately within national combination HIV prevention programmes – while collecting essential data on uptake, adherence and real-world impact. Additional WHO recommendations at IAS 2025 For the first time, WHO's treatment guidelines include a clear recommendation for the use of long-acting injectable cabotegravir and rilpivirine (CAB/RPV) as an alternative switching option for antiretroviral therapy (ART) for adults and adolescents who have achieved full viral suppression on oral ART and do not have active hepatitis B infection. This approach is designed to support people living with HIV facing adherence challenges to oral regimens. Updated guidelines on service delivery integration include recommendations to integrate HIV services with noncommunicable diseases (NCDs) such as hypertension and diabetes, as well as mental health care for depression, anxiety and alcohol use disorders into HIV services, alongside interventions to support ART adherence. Additionally, new guidelines on management of asymptomatic STIs recommend screening of gonorrhoea and/or chlamydia in key and priority populations. For people living with HIV who have mpox and are either ART naive or have experienced prolonged ART interruption, rapid initiation of ART is strongly recommended. Additionally, early HIV testing is advised for individuals presenting with suspected or confirmed mpox infection. WHO's standard operating procedures further emphasize HIV and syphilis testing for all individuals with suspected or confirmed mpox. In response to the broader challenges facing HIV programmes, WHO has also issued new operational guidance on sustaining priority HIV services in a changing funding landscape. The guidance aims to provide a stepwise framework to help countries prioritize services, assess risks, monitor disruptions, and adapt systems to protect health outcomes and preserve progress. 'We have the tools and the knowledge to end AIDS as a public health problem,' said Dr Meg Doherty, Director of WHO's Department of Global HIV, Hepatitis and STI Programmes and incoming Director of Science, Research, Evidence and Quality for Health. 'What we need now is bold implementation of these recommendations, grounded in equity and powered by communities.' HIV remains a major global public health issue. By the end of 2024, an estimated 40.8 million people were living with HIV with an estimated 65% in the WHO African Region. Approximately 630 000 people died from HIV-related causes globally, and an estimated 1.3 million people acquired HIV, including 120 000 children. Access to ART continues to expand, with 31.6 million people receiving treatment in 2024, up from 30.3 million in 2023. At a time of reduced funding for HIV and health, WHO's new and updated guidelines offer practical, evidence-based strategies to sustain momentum. By expanding prevention and treatment options, simplifying service delivery and promoting integration with broader health services, they support more efficient, equitable, and resilient HIV responses. Now is the moment for bold implementation to ensure these gains translate into real-world impact. Distributed by APO Group on behalf of World Health Organization (WHO).
The National
15 hours ago
- The National
UAE leads life-saving drive to tackle malnutrition in Yemen's Socotra
The UAE has joined forces with the World Health Organisation to lead a campaign to reduce the number of deaths caused by malnutrition on the Yemeni island of Socotra. Field teams from the UAE and the WHO have carried out assessments in the first phase of a drive aimed at bolstering health systems and improving patient care. Health workers have completed the first of four visits over the course of a year, as part of a mission to reduce the malnutrition death rate by up to 20 per cent within the next two to five years. The initiative is being carried out with the support of the Yemen's Ministry of Public Health and Population, state news agency Wam reported on Monday. The baseline assessment covered 38 villages across 29 subdistricts of Socotra, which has an estimated population of 60,000. Data was collected from 4,214 households, with field teams interviewing more than 900 care providers and taking anthropometric measurements from children and mothers. Such measurements are typically used to assess the height and weight of infants and adults. That data is an important indicator of nutrition and the risk of disease. The findings will be used to compile a report that will detail the maternal and child health and nutrition status of the community. It will also examine the readiness of healthcare sites to respond to emergency situations and meet the needs of patients. Future stages of the initiative will include the distribution of medical goods and other supplies, work by technical experts and service providers, and the launch of training programmes and community awareness campaigns. Remote island of global significance Socotra is part of one of the most isolated islands in the world. It is about 340km south-west of Yemen. While remote and small, it is known for its centuries-old, umbrella-shaped dragon blood trees and has been described as the Galapagos of the Indian Ocean because of its biodiversity. The Socotra Archipelago – made up of six islands, including its largest, Socotra – received Unesco World Heritage Site status in 2008 in recognition of its biodiversity and high number of endemic species. Socotra has endured a number of challenges in recent years, including two cyclones in 2015. The UAE provided $110 million in humanitarian aid to the people of Socotra from 2015 to 2021, offering assistance to its communities and helping to lay foundations for the future. The aid was delivered by organisations including the Emirates Red Crescent, the Abu Dhabi Fund for Development, the Khalifa bin Zayed Al Nahyan Foundation, the Sheikh Sultan bin Khalifa Al Nahyan Humanitarian and Scientific Foundation, and the Abu Dhabi Waste Management Centre. Key investment restored Socotra's airport and paid for the construction of two solar power stations, the establishment of four power plants and the installation of power generators in remote villages.
Zawya
16 hours ago
- Zawya
State-of-the-art laboratory enhances Madagascar's polio response
A new state-of-the-art laboratory has bolstered Madagascar's efforts to survey and detect polioviruses and effectively respond to the threat of the disease and protect children from its devastating impacts. The laboratory, which is fully accredited by World Health Organization (WHO), was handed over today to the national authorities. Hosted at the Institut Pasteur de Madagascar in the capital, Antananarivo, the laboratory reinforces the country's position as a regional pillar in rapid poliovirus detection and outbreak response. 'This commissioning symbolizes our collective commitment. It brings us closer to a future where no child in Madagascar—or anywhere—is at risk of polio,' said Dr Nely Alphonse José, head of plague, emerging and neglected tropical disease control department at the Ministry of Public Health. Established in 2023, the laboratory has significantly enhanced Madagascar's ability to rapidly detect poliovirus through both acute flaccid paralysis and environmental surveillance. Between 2022 and 2024, the laboratory detected more than 40 cases of circulating variant poliovirus type 1, enabling immediate and targeted immunization responses. The efforts played a key role in halting an outbreak of circulating variant poliovirus type 1. In May 2025, Madagascar marked two full years without any new detections of the virus, which meant the outbreak was declared closed after a thorough assessment. 'This laboratory is not only a national asset—it's a regional resource,' said Dr Laurent Musango, WHO Representative in Madagascar. 'With strengthened capacity and cutting-edge technology, Madagascar is now even better positioned to lead the charge against poliovirus transmission in Eastern and Southern Africa.' The handing over of the laboratory to the government marks a major step towards sustainable, country-led polio surveillance and self-sufficiency in managing future outbreaks and ensures strong measures are in place to sustain the country's polio-free status and contribute to the global goal of ending polio once and for all. Thanks to ongoing collaboration between national health authorities, WHO, and with support from the Gates Foundation, the laboratory has also joined pilot projects to deploy innovative tools such as direct detection through Nanopore sequencing – a new technology that boosts the speed and accuracy of viral identification, eliminating previous delays when samples had to be shipped abroad for genomic sequencing. WHO and its partners provided technical support, training, IT upgrades and environmental site optimization to strengthen the laboratory's operations—reinforcing national efforts to meet the objectives of the Global Polio Eradication Initiative. Accredited for viral isolation, intratypic differentiation and environmental surveillance, the laboratory is now a cornerstone in Madagascar's integrated disease surveillance system. It ensures timely data to guide vaccination campaigns and outbreak responses across the country. Distributed by APO Group on behalf of World Health Organization (WHO) - Madagascar.
